Anti-PD-1 associated retroperitoneal fibrosis

Rheumatology (Oxford). 2021 Sep 1;60(9):e329-e330. doi: 10.1093/rheumatology/keab264.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Retroperitoneal Fibrosis / chemically induced*
  • Retroperitoneal Fibrosis / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab
  • Methylprednisolone